Imperial College London

ProfessorPaoloMuraro

Faculty of MedicineDepartment of Brain Sciences

Professor of Neurology - Neuroimmunology and Immunotherapy
 
 
 
//

Contact

 

p.muraro Website

 
 
//

Location

 

E415Burlington DanesHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

242 results found

Mariottini A, Muraro PA, Saccardi R, 2023, Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?, MULTIPLE SCLEROSIS AND RELATED DISORDERS, Vol: 78, ISSN: 2211-0348

Journal article

Mariottini A, De Matteis E, Cencioni MT, Muraro PAAet al., 2023, Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances, CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, ISSN: 1528-4042

Journal article

Muraro PA, 2023, Resetting tolerance in autoimmune disease, SCIENCE, Vol: 380, Pages: 470-471, ISSN: 0036-8075

Journal article

Brittain G, Coles AJ, Giovannoni G, Muraro PA, Palace J, Petrie J, Roldan E, Scolding NJ, Snowden JA, Sharrack Bet al., 2023, Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?, PRACTICAL NEUROLOGY, Vol: 23, Pages: 139-+, ISSN: 1474-7758

Journal article

Mexhitaj I, Lim N, Fernandez-Velasco JI, Zrzavy T, Harris KM, Muraro PA, Villar LM, Bar -Or A, Cooney LAet al., 2022, Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials, JOURNAL OF IMMUNOLOGICAL METHODS, Vol: 510, ISSN: 0022-1759

Journal article

Karoui H, Cencioni M, Cole J, Wood D, Booth T, Mallon D, Eshaghi A, Ciccarelli O, Muraro P, Nicholas Ret al., 2022, Novel multiple sclerosis magnetic resonance imagingderived subtypes are associated with alterations in immunological blood biomarkers in a highly active relapsing-remitting cohort, 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: 24-24, ISSN: 1352-4585

Conference paper

Brittain G, Glover R, Roldan E, Papaioannou D, Cooper C, Muraro P, Snowden J, Sharrack Bet al., 2022, A changing target - adapting ongoing autologous haematopoietic stem cell transplantation clinical trials to evolving clinical practice in the treatment of highly active relapsing remitting multiple sclerosis, 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: 843-843, ISSN: 1352-4585

Conference paper

Mariottini A, Muraro PA, Luenemann JD, 2022, Antibody-mediated cell depletion therapies in multiple sclerosis, FRONTIERS IN IMMUNOLOGY, Vol: 13, ISSN: 1664-3224

Journal article

Goklemez S, Hasni S, Hakim FT, Muraro PA, Pirsl F, Rose J, Memon S, Fowler DF, Steinberg SM, Baker EH, Panch SR, Gress R, Illei GG, Lipsky PE, Pavletic SZet al., 2022, Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus, RHEUMATOLOGY, Vol: 61, Pages: 3317-3328, ISSN: 1462-0324

Journal article

Ruck T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C, Schroeter CB, Willison A, Heming M, Muentefering T, Melzer N, Kraemer J, Lindner M, Riepenhausen M, Gross CC, Klotz L, Bittner S, Muraro PA, Schneider-Hohendorf T, Schwab N, Meyer zu Hoerste G, Goebels N, Meuth SG, Wiendl Het al., 2022, Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity, BRAIN, Vol: 145, Pages: 1711-1725, ISSN: 0006-8950

Journal article

Polidoro F, Zito A, Neo C, Rigoni E, Singh-Curry V, Nandoskar A, Malik O, Dorsey R, Muraro P, Scalfari A, Nicholas Ret al., 2022, PIRA among MS Patients Treated with Ocrelizumab and Alemtuzumab; A Real World Study, Publisher: SAGE PUBLICATIONS LTD, Pages: 174-175, ISSN: 1352-4585

Conference paper

Zito A, Polidoro F, Neo C, Rigoni E, Singh-Curry V, Nandoskar A, Dorsey R, Bergamaschi R, Muraro PA, Nicholas R, Scalfari Aet al., 2022, Clinical and radiological outcomes among MS patients treated with Alemtuzumab and Ocrelizumab: a Real World Experience, Publisher: SAGE PUBLICATIONS LTD, Pages: 171-172, ISSN: 1352-4585

Conference paper

Cencioni MT, Genchi A, Brittain G, de Silva TI, Sharrack B, Snowden JA, Alexander T, Greco R, Muraro PAet al., 2022, Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party, FRONTIERS IN IMMUNOLOGY, Vol: 12, ISSN: 1664-3224

Journal article

Jacobs SAH, Muraro PA, Cencioni MT, Knowles S, Cole JH, Nicholas Ret al., 2022, Worse Physical Disability Is Associated With the Expression of PD-1 on Inflammatory T-Cells in Multiple Sclerosis Patients With Older Appearing Brains, FRONTIERS IN NEUROLOGY, Vol: 12, ISSN: 1664-2295

Journal article

Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, Clanet M, Fernandez O, Marriot J, Muraro P, Nabavi SM, Oliveri RS, Radue E, Tello CR, Schiavetti I, Sellner J, Sorensen PS, Sormani MP, Wuerfel JT, Freedman MSet al., 2021, Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial, LANCET NEUROLOGY, Vol: 20, Pages: 917-929, ISSN: 1474-4422

Journal article

Alexander T, Snowden JA, Burman J, Chang H-D, Del Papa N, Farge D, Lindsay JO, Malard F, Muraro PA, Nitti R, Salas A, Sharrack B, Mohty M, Greco Ret al., 2021, Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT, FRONTIERS IN ONCOLOGY, Vol: 11, ISSN: 2234-943X

Journal article

Nicholas RS, Rhone EE, Mariottini A, Silber E, Malik O, Singh-Curry V, Turner B, Scalfari A, Ciccarelli O, Sormani MP, Olavarria E, Mehra V, Gabriel I, Kazmi MA, Muraro Pet al., 2021, Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis, NEUROLOGY, Vol: 97, Pages: E890-E901, ISSN: 0028-3878

Journal article

Greco R, Alexander T, Burman J, Del Papa N, de Vries-Bouwstra J, Farge D, Henes J, Kazmi M, Kirgizov K, Muraro PA, Ricart E, Rovira M, Saccardi R, Sharrack B, Snarski E, Withers B, Jessop H, Boglione C, Kramer E, Badoglio M, Labopin M, Orchard K, Corbacioglu S, Ljungman P, Mikulska M, De la Camara R, Snowden JAet al., 2021, Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations, BONE MARROW TRANSPLANTATION, Vol: 56, Pages: 1493-1508, ISSN: 0268-3369

Journal article

Burt RK, Muraro PA, Farge D, Oliveira MC, Snowden JA, Saccardi R, Han X, Quigley K, Bueno V, Frasca D, Fedorenko D, Burman Jet al., 2021, New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis, BONE MARROW TRANSPLANTATION, Vol: 56, Pages: 1509-1517, ISSN: 0268-3369

Journal article

Cencioni MT, Ali R, Nicholas R, Muraro PAet al., 2021, Defective CD19+CD24<SUP>hi</SUP>CD38<SUP>hi</SUP>transitional B-cell function in patients with relapsing-remitting MS, MULTIPLE SCLEROSIS JOURNAL, Vol: 27, Pages: 1187-1197, ISSN: 1352-4585

Journal article

Cencioni MT, Mattoscio M, Magliozzi R, Bar-Or A, Muraro PAet al., 2021, B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies, NATURE REVIEWS NEUROLOGY, Vol: 17, Pages: 399-414, ISSN: 1759-4758

Journal article

Amoriello R, Chernigovskaya M, Greiff V, Carnasciali A, Massacesi L, Barilaro A, Repice AM, Biagioli T, Aldinucci A, Muraro PA, Laplaud DA, Lossius A, Ballerini Cet al., 2021, TCR repertoire diversity in Multiple Sclerosis: High-dimensional bioinformatics analysis of sequences from brain, cerebrospinal fluid and peripheral blood, EBioMedicine, Vol: 68, Pages: 103429-103429, ISSN: 2352-3964

BACKGROUND: T cells play a key role in the pathogenesis of multiple sclerosis (MS), a chronic, inflammatory, demyelinating disease of the central nervous system (CNS). Although several studies recently investigated the T-cell receptor (TCR) repertoire in cerebrospinal fluid (CSF) of MS patients by high-throughput sequencing (HTS), a deep analysis on repertoire similarities and differences among compartments is still missing. METHODS: We performed comprehensive bioinformatics on high-dimensional TCR Vβ sequencing data from published and unpublished MS and healthy donors (HD) studies. We evaluated repertoire polarization, clone distribution, shared CDR3 amino acid sequences (CDR3s-a.a.) across repertoires, clone overlap with public databases, and TCR similarity architecture. FINDINGS: CSF repertoires showed a significantly higher public clones percentage and sequence similarity compared to peripheral blood (PB). On the other hand, we failed to reject the null hypothesis that the repertoire polarization is the same between CSF and PB. One Primary-Progressive MS (PPMS) CSF repertoire differed from the others in terms of TCR similarity architecture. Cluster analysis splits MS from HD. INTERPRETATION: In MS patients, the presence of a physiological barrier, the blood-brain barrier, does not impact clone prevalence and distribution, but impacts public clones, indicating CSF as a more private site. We reported a high Vβ sequence similarity in the CSF-TCR architecture in one PPMS. If confirmed it may be an interesting insight into MS progressive inflammatory mechanisms. The clustering of MS repertoires from HD suggests that disease shapes the TCR Vβ clonal profile. FUNDING: This study was partly financially supported by the Italian Multiple Sclerosis Foundation (FISM), that contributed to Ballerini-DB data collection (grant #2015 R02).

Journal article

Roberts F, Hobbs H, Jessop H, Bozzolini C, Burman J, Greco R, Ismail A, Kazmi M, Kirgizov K, Mancardi G, Mawson S, Muraro PA, Puyade M, Saccardi R, Withers B, Verhoeven B, Sharrack B, Snowden JAet al., 2020, Rehabilitation before and after Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for patients with Multiple Sclerosis (MS): consensus guidelines and recommendations for best clinical practice on behalf of the autoimmune diseases working party, nurses group, and patient advocacy committee of the European Society for Blood and Marrow Transplantation (EBMT), Frontiers in Neurology, Vol: 11, Pages: 1-13, ISSN: 1664-2295

Autologous haematopoietic stem cell transplantation (AHSCT) is increasingly used to treat people with multiple sclerosis (MS). Supported by an evolving evidence base, AHSCT can suppress active inflammation in the central nervous system and induce long-term changes in immune cell populations, thereby stabilizing, and, in some cases, reversing disability in carefully selected MS patients. However, AHSCT is an intensive chemotherapy-based procedure associated with intrinsic risks, including profound cytopenia, infection, and organ toxicity, accompanied by an on-going degree of immuno-compromise and general deconditioning, which can be associated with a transient increase in functional impairment in the early stages after transplantation. Although international guidelines and recommendations have been published for clinical and technical aspects of AHSCT in MS, there has been no detailed appraisal of the rehabilitation needed following treatment nor any specific guidelines as to how this is best delivered by hospital and community-based therapists and wider multidisciplinary teams in order to maximize functional recovery and quality of life. These expert consensus guidelines aim to address this unmet need by summarizing the evidence-base for AHSCT in MS and providing recommendations for current rehabilitation practice along with identifying areas for future research and development.

Journal article

Sharrack B, Snowden J, Muraro P, 2020, Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (starms), 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 209-210, ISSN: 1352-4585

Conference paper

Neo C, Singh-Curry V, Nandoskar A, Malik O, Dorsey R, Muraro P, Nicholas R, Scalfari Aet al., 2020, Real-world data on the use of ocrelizumab, among ms patients: b-cell suppression and clinical outcomes, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 185-186, ISSN: 1352-4585

Conference paper

Rigoni E, Singh-Curry V, Nandoskar A, Malik O, Dorsey-Campbell R, Bergamaschi R, Muraro P, Nicholas R, Scalfari Aet al., 2020, Real world evidence of progression independent of relapsing activity among ms patients treated with alemtuzumab, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 547-547, ISSN: 1352-4585

Conference paper

Iacobaeus E, Arrambide G, Amato MP, Derfuss T, Vukusic S, Hemmer B, Tintore M, Brundin L, 2018 ECTRIMS Focused Workshop Groupet al., 2020, Aggressive multiple sclerosis (1): Towards a definition of the phenotype., Multiple Sclerosis Journal, Vol: 26, Pages: 1031-1044, ISSN: 1352-4585

While the major phenotypes of multiple sclerosis (MS) and relapsing-remitting, primary and secondary progressive MS have been well characterized, a subgroup of patients with an active, aggressive disease course and rapid disability accumulation remains difficult to define and there is no consensus about their management and treatment. The current lack of an accepted definition and treatment guidelines for aggressive MS triggered a 2018 focused workshop of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on aggressive MS. The aim of the workshop was to discuss approaches on how to describe and define the disease phenotype and its treatments. Unfortunately, it was not possible to come to consensus on a definition because of unavailable data correlating severe disease with imaging and molecular biomarkers. However, the workshop highlighted the need for future research needed to define this disease subtype while also focusing on its treatment and management. Here, we review previous attempts to define aggressive MS and present characteristics that might, with additional research, eventually help characterize it. A companion paper summarizes data regarding treatment and management.

Journal article

Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M, 2018 ECTRIMS Focused Workshop Groupet al., 2020, Aggressive multiple sclerosis (2): Treatment., Multiple Sclerosis Journal, Vol: 26, Pages: 1045-1063, ISSN: 1352-4585

The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.

Journal article

Mariottini A, De Matteis E, Muraro PA, 2020, Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status, BIODRUGS, Vol: 34, Pages: 307-325, ISSN: 1173-8804

Journal article

Cohen JA, Georges GE, Griffith LM, Steinmiller K, Barry WT, Harris KM, Ryker K, Rice J, Tosta P, McCarthy S, Goldstein JS, McNamara J, Miller D, Carlson JJ, Arnold DL, Smilek DE, Muraro PAet al., 2020, Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation For Multiple Sclerosis, Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, Publisher: SAGE PUBLICATIONS LTD, Pages: 39-40, ISSN: 1352-4585

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00497822&limit=30&person=true